NuGene International, Inc. Selects Capital Market Relations For Strategic Investor Relations

IRVINE, Calif., Feb. 26, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation, has announced that it has selected Capital Market Relations as agency of record for investor relations and strategic communications.

"NuGene continues to improve our distribution, sales and diversification strategies and we need to communicate our activities to current and prospective shareholders," stated Ali Kharazmi CEO of NuGene when announcing this agency selection. "We wanted a firm that has experience working with innovative companies that can inform, educate and communicate our passion to both the professional and general investment communities."

Capital Market Relations, headed by Chris Rosgen, specifically focuses on companies that are disrupting existing market models through innovation and technology. The firm has established strong relationships with institutions, investors and the analysts that cover these types of companies.

"I am excited by what NuGene is doing in the skin and hair care markets, and I envision a broad range of opportunities for their stem cell based technologies with BioPharma," said Rosgen. "I am very passionate about companies that are developing and delivering new standards of care. We specialize in helping disruptive companies like NuGene develop and implement proactive strategies to effectively interact with global capital markets."

Capital Market Relations will soon be releasing a Capital Market Report, a comprehensive executive summary, on NuGene International, Inc. which will be available through the website at www.capitalmarketreport.com.

About NuGene International, Inc.

Nugene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.   The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.These forward-looking statements generally can be identified by use of phrases or terminology such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "target," "will," "would," "look forward" and other similar words or expressions, or expressions, or the negative of these words or similar words or expressions. Similarly, descriptions of NuGene's objectives, strategies, plans or goals or targets contained herein are also considered forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission from time to time, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information whether as a result of new information, future events or otherwise. All of the forward-looking statements contained herein speak only as of the date of this release.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949)481-9739

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nugene-international-inc-selects-capital-market-relations-for-strategic-investor-relations-300042115.html

SOURCE NuGene International, Inc.